在脉冲场废除过程中自发呼吸中使用静脉胺对深度镇静的研究
Saverio Iacopino1, Pasquale Filannino1, Paolo Artale1
1Maria Cecilia Hospital, Cotignola, Italy.
Journal of cardiothoracic and vascular anesthesia
|November 12, 2023
概括
这项研究表明,用胺激素进行深度镇静对于心房动 (AF) 的脉冲场移除 (PFA) 是安全有效的. 患者和操作人员对这种麻醉方案表示高度满意.
科学领域:
- 心脏病学 心脏病学
- 麻醉学 麻醉学
- 医疗器械 医疗器械
背景情况:
- 心房动 (AF) 是一种常见的心律失常,需要治疗.
- 脉冲场切除 (PFA) 是一种新兴的AF治疗方法.
- 深度镇静通常是必要的AF剥离程序.
研究的目的:
- 为了评估使用胺在PFA期间对AF进行深度镇静方案.
- 评估这种镇静策略的安全性和有效性.
- 为了确定患者和操作员对该协议的满意度.
主要方法:
- 一项观察性,前性,非随机化研究在一个中心进行.
- 117名连续接受PFA治疗AF的患者接受了静脉注射胺的深度镇静.
- 该方案涉及芬太尼,米达佐拉姆和胺,并监测镇静水平和疼痛.
主要成果:
- 在所有患者中,通过PFA实现了肺静脉隔离.
- 平均镇静时间约为55分钟,大多数患者的镇静时间不到一个小时.
- 报告了高的患者和操作员满意度 (98.2%) 和低的疼痛评分 (≤3).
- 没有发生重大手术或麻醉相关的并发症.
结论:
- 一个标准化的深度镇静协议与胺是安全和有效的PFA在AF患者.
- 该协议确保了最佳的患者和操作员满意度.
- 这种方法利用快速开始和抵消的药物来有效地管理麻醉.
更多相关视频
08:16Optogenetic Activation of Afferent Pathways in Brain Slices and Modulation of Responses by Volatile Anesthetics
Published on: July 23, 2020
2.2K
05:39Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia
Published on: May 26, 2023
1.5K
相关概念视频
Stages of General Anesthesia
Various sedation levels offer significant advantages in facilitating procedural interventions for patients undergoing medical or invasive surgical procedures. These levels span from anxiolysis to general anesthesia, providing a spectrum of sedative effects to cater to specific patient needs. Anxiolysis reduces anxiety and is achieved through minimal sedation, enabling patients to remain awake and responsive while feeling more at ease during the procedure. This level can benefit minor...
Parenteral Anesthetics: Overview
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
